Cellular Origins Collaborates with ScaleReady for Cell and Gene Therapies
The objective of the partnership is to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer.
Cellular Origins announced its collaborative partnership with ScaleReady on May 11, 2023 to further bring together process development expertise, tools, and technologies for scalable cell and gene therapies (CGT) manufacturing. The objective of the partnership is to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer, according to the press release.
The first project in the collaboration will be to standardize and automate interconnections between the modules of ScaleReady’s G-Rex, which is a manufacturing platform used by therapy developers internationally to produce CGTs for clinical trials, including the most recently approved commercial therapies. Further, integrating Cellular Origins’ robotic system will help to eliminate variability in manual connection techniques, the company says. According to the press release, these projects will automate additional areas of ScaleReady’s workflow, like the robotic movement of G-Rex into and out of incubators.
“ScaleReady’s technologies are widely adopted in the production of advanced, cell-based therapies. This collaboration demonstrates the adaptability of our robotic system, highlighting that it can be integrated seamlessly into existing workflows and allowing therapy developers access to scalable, cost-effective advanced therapy manufacture without significant process redevelopment,” said Edwin Stone, PhD, CEO of Cellular Origins, in a press release.
Source: BusinessWire
